Pay in 4 interest-free payments of $7.25 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Calculator Use a research-context reconstitution calculator to confirm draw volumes any time you change vial size or BAC water volume
HRD1-mediated degradation of Acly reduces hepatic lipid accumulation, thereby mitigating MASLD and reinforcing ERADs protective role against metabolic liver disease
Is KPV proven to treat inflammatory bowel disease
The investigator's previous results and those of others suggest that GSH depletion is a general phenomenon of aging tissues and organisms
Following administration in animal models: BPC-157 demonstrates rapid systemic distribution within 15-30 minutes with unusual oral bioavailability TB-500 shows tissue-specific accumulation with preferential uptake in injured areas GHK-Cu exhibits copper-mediated transport and gene-modulating tissue binding KPV utilizes PepT1 transporter-mediated uptake with enhanced delivery to inflamed tissues Combined formulation provides immediate, sustained, and targeted bioactivity across multiple mechanisms Distribution studies suggest that injury sites and inflamed tissues tend to concentrate multiple components through different mechanisms BPC-157 through injury-site targeting, TB-500 through actin-rich repair zones, GHK-Cu through copper-dependent pathways, and KPV through upregulated PepT1 in inflammation, potentially enhancing local therapeutic effects
US$ 27.32
US$ 29.61
US$ 27.97
US$ 25.90
